These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 34930657)

  • 1. Medication Trajectory and Treatment Patterns in Medicare Patients With Heart Failure and Reduced Ejection Fraction.
    Mentz RJ; Lautsch D; Pulungan Z; Kim S; Hilkert R; Teigland C; Yang M; Djatche L
    J Card Fail; 2022 Aug; 28(8):1349-1354. PubMed ID: 34930657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frailty and uptake of angiotensin receptor neprilysin inhibitor for heart failure with reduced ejection fraction.
    Lee YC; Lin JK; Ko D; Cheng S; Patorno E; Glynn RJ; Tsacogianis T; Kim DH
    J Am Geriatr Soc; 2023 Oct; 71(10):3110-3121. PubMed ID: 37345734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guideline-Directed Medical Therapy in Newly Diagnosed Heart Failure With Reduced Ejection Fraction in the Community.
    Dunlay SM; Killian JM; Roger VL; Schulte PJ; Blecker SB; Savitz ST; Redfield MM
    J Card Fail; 2022 Oct; 28(10):1500-1508. PubMed ID: 35902033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex Disparities in Longitudinal Use and Intensification of Guideline-Directed Medical Therapy Among Patients With Newly Diagnosed Heart Failure With Reduced Ejection Fraction.
    Sumarsono A; Xie L; Keshvani N; Zhang C; Patel L; Alonso WW; Thibodeau JT; Fonarow GC; Van Spall HGC; Messiah SE; Pandey A
    Circulation; 2024 Feb; 149(7):510-520. PubMed ID: 38258605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mortality and guideline-directed medical therapy in real-world heart failure patients with reduced ejection fraction.
    McCullough PA; Mehta HS; Barker CM; Van Houten J; Mollenkopf S; Gunnarsson C; Ryan M; Cork DP
    Clin Cardiol; 2021 Sep; 44(9):1192-1198. PubMed ID: 34342033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment patterns of patients with worsening heart failure with reduced ejection fraction.
    Greene SJ; Gaggin HK; Zhou M; Bash LD; Lautsch D; Djatche L; Song Y; Signorovitch J; Stevenson AS; Blaustein RO; Butler J
    ESC Heart Fail; 2024 Aug; 11(4):1932-1946. PubMed ID: 38639469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Out-of-pocket payments for part d covered medications by medicare fee-for-service beneficiaries with heart failure with reduced ejection fraction.
    Fendrick AM; Djatche L; Pulungan Z; Teigland C; Yang M; Lautsch D; Hilkert R; Mentz R
    Am Heart J; 2022 Apr; 246():74-81. PubMed ID: 34774543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction.
    Butler J; Yang M; Manzi MA; Hess GP; Patel MJ; Rhodes T; Givertz MM
    J Am Coll Cardiol; 2019 Mar; 73(8):935-944. PubMed ID: 30819362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF Registry.
    Greene SJ; Butler J; Hellkamp AS; Spertus JA; Vaduganathan M; Devore AD; Albert NM; Patterson JH; Thomas L; Williams FB; Hernandez AF; Fonarow GC
    J Card Fail; 2022 Mar; 28(3):370-384. PubMed ID: 34793971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eligibility and Projected Benefits of Rapid Initiation of Quadruple Therapy for Newly Diagnosed Heart Failure.
    Greene SJ; Ayodele I; Pierce JB; Khan MS; Lewsey SC; Yancy CW; Alhanti B; Van Spall HGC; Allen LA; Fonarow GC
    JACC Heart Fail; 2024 Aug; 12(8):1365-1377. PubMed ID: 38597866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities.
    Albert NM; Tyson RJ; Hill CL; DeVore AD; Spertus JA; Duffy C; Butler J; Patterson JH; Hernandez AF; Williams FB; Thomas L; Fonarow GC
    Am Heart J; 2021 May; 235():82-96. PubMed ID: 33497697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guideline-directed medical therapy for HFrEF: sequencing strategies and barriers for life-saving drug therapy.
    Malgie J; Clephas PRD; Brunner-La Rocca HP; de Boer RA; Brugts JJ
    Heart Fail Rev; 2023 Sep; 28(5):1221-1234. PubMed ID: 37311917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-centered Outcomes in HFrEF Following a Worsening Heart Failure Event: A Survey Analysis.
    Dunbar SB; Tan X; Lautsch D; Yang M; Ricker B; Maculaitis MC; Nagle T; Clark LT; Hilkert R; Brady JE; Spertus JA
    J Card Fail; 2021 Aug; 27(8):877-887. PubMed ID: 34364664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns, Prognostic Implications, and Rural-Urban Disparities in Optimal GDMT Following HFrEF Diagnosis Among Medicare Beneficiaries.
    Mentias A; Keshvani N; Sumarsono A; Desai R; Khan MS; Menon V; Hsich E; Bress AP; Jacobs J; Vasan RS; Fonarow GC; Pandey A
    JACC Heart Fail; 2024 Jun; 12(6):1044-1055. PubMed ID: 37943222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing Guideline-Directed Medication Therapy for Heart Failure in End-Stage Renal Disease.
    Cutshall BT; Duhart BT; Saikumar J; Samarin M; Hutchison L; Hudson JQ
    Am J Med Sci; 2018 Mar; 355(3):247-251. PubMed ID: 29549927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF: The CHAMP-HF Registry.
    Vaduganathan M; Fonarow GC; Greene SJ; DeVore AD; Kavati A; Sikirica S; Albert NM; Duffy CI; Hill CL; Patterson JH; Spertus JA; Thomas LE; Williams FB; Hernandez AF; Butler J
    JACC Heart Fail; 2020 Jun; 8(6):469-480. PubMed ID: 32387066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the Usage and Dosing of Guideline-Directed Medical Therapy for Heart Failure With Reduced Ejection Fraction Patients in Clinical Practice.
    Smith KV; Dunning JR; Fischer CM; MacLean TE; Bosque-Hamilton JW; Fera LE; Grant JY; Zelle DJ; Matta L; Gaziano TA; MacRae CA; Scirica BM; Desai AS
    J Pharm Pract; 2022 Oct; 35(5):747-751. PubMed ID: 33813934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality outcomes, healthcare resource utilization and costs in Medicare patients with chronic heart failure with reduced ejection fraction with and without a worsening event.
    Mentz RJ; Pulungan Z; Kim S; Yang M; Teigland C; Hilkert R; Djatche LM
    J Med Econ; 2021; 24(1):698-705. PubMed ID: 33900874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of medical therapy in patients with heart failure with reduced ejection fraction.
    Kocabaş U; Ergin I; Kıvrak T; Yılmaz Öztekin GM; Tanık VO; Özdemir İ; Avcı Demir F; Doğduş M; Şen T; Altınsoy M; Üstündağ S; Urgun ÖD; Sinan ÜY; Uygur B; Yeni M; Özçalık E
    ESC Heart Fail; 2023 Dec; 10(6):3677-3689. PubMed ID: 37804042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry.
    Greene SJ; Butler J; Albert NM; DeVore AD; Sharma PP; Duffy CI; Hill CL; McCague K; Mi X; Patterson JH; Spertus JA; Thomas L; Williams FB; Hernandez AF; Fonarow GC
    J Am Coll Cardiol; 2018 Jul; 72(4):351-366. PubMed ID: 30025570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.